MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek; Chih Cheng Chen; Miklós Egyed; Martin Ellis; Laura Fox; Yeow T. Goh; Vikas Gupta; Claire Harrison; Jean Jacques Kiladjian; Mihaela C. Lazaroiu; Adam Mead; Donal McLornan; Mary F. McMullin; Stephen T. Oh; Andrew Perkins; Uwe Platzbecker; Christof Scheid; Alessandro Vannucchi; Sung Soo Yoon; Mark M. Kowalski; Ruben A. Mesa

doi:10.2217/fon-2020-1048

MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek, Chih Cheng Chen, Miklós Egyed, Martin Ellis, Laura Fox, Yeow T. Goh, Vikas Gupta, Claire Harrison, Jean Jacques Kiladjian, Mihaela C. Lazaroiu, Adam Mead, Donal McLornan, Mary F. McMullin, Stephen T. Oh, Andrew Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Vannucchi, Sung Soo Yoon, Mark M. Kowalski^*Ruben A. Mesa

^*此作品的通信作者

研究成果: 期刊稿件 › 文章 › 同行評審

38 引文斯高帕斯（Scopus）

摘要

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

原文	英語
頁（從 - 到）	1449-1458
頁數	10
期刊	Future Oncology
卷	17
發行號	12
DOIs	https://doi.org/10.2217/fon-2020-1048
出版狀態	已出版 - 04 2021
對外發佈	是

文獻附註

Publisher Copyright:
© 2021 Future Oncology. All rights reserved.

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.2217/fon-2020-1048

其它文件與鏈接

Link to publication in Scopus

引用此

Verstovsek, S., Chen, C. C., Egyed, M., Ellis, M., Fox, L., Goh, Y. T., Gupta, V., Harrison, C., Kiladjian, J. J., Lazaroiu, M. C., Mead, A., McLornan, D., McMullin, M. F., Oh, S. T., Perkins, A., Platzbecker, U., Scheid, C., Vannucchi, A., Yoon, S. S., ... Mesa, R. A. (2021). MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 17(12), 1449-1458. https://doi.org/10.2217/fon-2020-1048

@article{6150de7828b146ce8bb9d0e8798ae6e1,

title = "MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic",

abstract = "Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.",

keywords = "ACVR1, JAK inhibitor, Phase III clinical trial, anemia, danazol, hemoglobin, momelotinib, myelofibrosis, transfusion",

author = "Srdan Verstovsek and Chen, {Chih Cheng} and Mikl{\'o}s Egyed and Martin Ellis and Laura Fox and Goh, {Yeow T.} and Vikas Gupta and Claire Harrison and Kiladjian, {Jean Jacques} and Lazaroiu, {Mihaela C.} and Adam Mead and Donal McLornan and McMullin, {Mary F.} and Oh, {Stephen T.} and Andrew Perkins and Uwe Platzbecker and Christof Scheid and Alessandro Vannucchi and Yoon, {Sung Soo} and Kowalski, {Mark M.} and Mesa, {Ruben A.}",

year = "2021",

month = apr,

doi = "10.2217/fon-2020-1048",

language = "英语",

volume = "17",

pages = "1449--1458",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

Verstovsek, S, Chen, CC, Egyed, M, Ellis, M, Fox, L, Goh, YT, Gupta, V, Harrison, C, Kiladjian, JJ, Lazaroiu, MC, Mead, A, McLornan, D, McMullin, MF, Oh, ST, Perkins, A, Platzbecker, U, Scheid, C, Vannucchi, A, Yoon, SS, Kowalski, MM & Mesa, RA 2021, 'MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic', Future Oncology, 卷 17, 編號 12, 頁 1449-1458. https://doi.org/10.2217/fon-2020-1048

TY - JOUR

T1 - MOMENTUM

T2 - Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

AU - Verstovsek, Srdan

AU - Chen, Chih Cheng

AU - Egyed, Miklós

AU - Ellis, Martin

AU - Fox, Laura

AU - Goh, Yeow T.

AU - Gupta, Vikas

AU - Harrison, Claire

AU - Kiladjian, Jean Jacques

AU - Lazaroiu, Mihaela C.

AU - Mead, Adam

AU - McLornan, Donal

AU - McMullin, Mary F.

AU - Oh, Stephen T.

AU - Perkins, Andrew

AU - Platzbecker, Uwe

AU - Scheid, Christof

AU - Vannucchi, Alessandro

AU - Yoon, Sung Soo

AU - Kowalski, Mark M.

AU - Mesa, Ruben A.

PY - 2021/4

Y1 - 2021/4

N2 - Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

AB - Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

KW - ACVR1

KW - JAK inhibitor

KW - Phase III clinical trial

KW - anemia

KW - danazol

KW - hemoglobin

KW - momelotinib

KW - myelofibrosis

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=85103060890&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-1048

DO - 10.2217/fon-2020-1048

M3 - 文章

C2 - 33423550

AN - SCOPUS:85103060890

SN - 1479-6694

VL - 17

SP - 1449

EP - 1458

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

摘要

文獻附註

UN SDG

存取文件

其它文件與鏈接

指紋

引用此